Category: Oncology

Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer

Dr. Lisa Butterfield, PhD recently joined the Parker Institute for Cancer Immunotherapy as Vice President focusing on cell therapies while she continues her independent cancer vaccine research as an Adjunct Professor of Microbiology and Immunology at the University of California,...

Q&A with Drs. Torsten Nielsen and Tony Ng and Angela Goytain: Development of a Sarcoma Gene Fusion Assay Faster Than FISH and Simpler than NGS

The NanoString nCounter is Research Use Only and not for diagnostic use. The views expressed herein are solely those of the interviewed researchers. Torsten Nielsen, MD, PhD is a pathologist and clinical scientist at the University of British Columbia (BC)...

Q&A with Dr. Juliane Nguyen: Exosome Profiling with miRNA and Biotech’s Next Breakthrough

Dr. Juliane Nguyen is a professor in the Department of Pharmaceutical Sciences at the University of Buffalo. Her Therapeutic Biomaterials Laboratory investigates using exosomes and other nanoscale carriers for the treatment of diseases including cancer and ischemic heart disease. NanoString...

The IO Revolution, Part 3 of 4: The Role of the Tumor in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. Part two further examined the role of the host, and in this blog, we consider the role of the tumor in the...

/ March 9, 2017

The IO Revolution, Part 2 of 4: The Role of the Host in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these sources of inter-patient heterogeneity has the potential to influence the...

/ January 12, 2017